IL2 and HIV infectious disease: Similarly, treatment of peripheral blood mononuclear cells (PBMCs) with SP-D during HIV infection decreased IL-2, IFN-γ, VEGF, IL-6, monocyte chemoattractant protein-1 (MCP-1) and IL-1β (52).